A study in the Journal of Diabetes Investigation showed that 15.5% and 13.7% of Asian adults with type 2 diabetes and cardiovascular disease who received empagliflozin had worsening nephropathy and progressed to macroalbuminuria, respectively, compared with 21.8% and 19.3% of those on placebo. Japanese researchers conducted a post hoc analysis of 1,517 diabetes patients from the EMPA-REG OUTCOME study and found that the empagliflozin group also had an increased estimated glomerular filtration rate over 192 weeks and a reduced urine albumin to creatinine ratio at weeks 12 through 164.
Study examines kidney outcomes in diabetes patients on empagliflozin
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.